Plain-English translation of NCT06995898 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
The Vanguard Study is testing two new blood tests—called Shield and Avantect—designed to detect cancer early by finding circulating tumor DNA (cancer signals) in your blood. Researchers want to learn whether these tests can identify cancer before symptoms appear, and how well they work compared to current screening methods. This is one of the largest studies of its kind, enrolling 24,000 people across many sites.
Most cancers are easier to treat when caught early, but current screening methods don't exist for many cancer types or miss some cases. These new blood tests could offer a simpler, less invasive way to screen for multiple cancers at once, potentially helping doctors find disease sooner and save lives.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic twice: once at the start to give a blood sample and complete questionnaires, and again after one year. Some participants will receive their blood test results immediately (unblinded sites), while others will only receive results if they're abnormal (blinded sites). If your test is abnormal, your doctor will follow up with additional testing. You'll also allow researchers to review your medical records. The study lasts one year, though researchers may track health outcomes longer.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
United States